Market
Dexcom tweaks full-year outlook after reporting 13% growth in Q2
Dexcom reported 13% revenue growth in Q2 and adjusted its full-year outlook upward following the earnings release on July 30. The company's Nasdaq shares rose over 8% to $81.04 at market open July 31, reflecting investor confidence in the revised guidance.
The source
This brief is a MedIndexer summary of reporting by Medical Device Network. To read the full story, head to the source.
Read the full story at Medical Device Network